| Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). | |
| | |
MedLine Citation:
|
PMID: 12850477 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and accounts for 20% of pediatric leukemia. Although conventional chemotherapy induces clinical remissions in most patients with AML, recurrent leukemia represents the major obstacle to cure. Conventional chemotherapy reinduction is associated with limited efficacy and substantial toxicity. Chemotherapy specifically targeted to leukemic cells by monoclonal antibodies might enable patients to achieve remissions more safely than conventional approaches. After evaluating a series of phase II studies, the U.S. Food and Drug Administration approved Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered candidates for other types of cytotoxic chemotherapy. Among 277 adult patients with CD33-positive AML in first relapse, 26% experienced an overall response after Mylotarg monotherapy. Despite the fact that myelosuppression, hyperbilirubinemia, and elevated hepatic transaminases were commonly observed, the incidences of severe infections and mucositis were relatively low in comparison with conventional chemotherapeutic treatment. Preliminary reports in pediatric patients also report Mylotarg to be reasonably well tolerated. Recently, data from study regimens combining Mylotarg and conventional chemotherapy suggest an unusually high remission induction rate in de novo AML patients. Information assembled from prospective, ongoing studies in the United States and the United Kingdom should help us use this novel immunoconjugate in a safe and effective manner. |
| | |
Authors:
|
Eric L Sievers |
Related Documents
:
|
16612767 - Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. 20652967 - Day 15 bone marrow driven double induction in young adult patients with acute myeloid l... 2866667 - Clostridium perfringens septicemia and acute leukemia. 22559997 - Determining safe alternatives for multidrug hypersensitive patients with the alternativ... 1839717 - More munchausen with chronic pain. 2068467 - Retrospective clinical study of hypersensitivity reactions to aztreonam and six other b... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Blood cells, molecules & diseases Volume: 31 ISSN: 1079-9796 ISO Abbreviation: Blood Cells Mol. Dis. Publication Date: 2003 Jul-Aug |
Date Detail:
|
Created Date: 2003-07-09 Completed Date: 2004-04-30 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9509932 Medline TA: Blood Cells Mol Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 7-10 Citation Subset: IM |
Affiliation:
|
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. esievers@fhcrc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Aminoglycosides / therapeutic use* Antibodies, Monoclonal / therapeutic use* Antineoplastic Agents / therapeutic use Clinical Trials as Topic Drug Approval Humans Immunotoxins / therapeutic use* Leukemia, Myeloid / drug therapy*, mortality, pathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Aminoglycosides; 0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Immunotoxins; 0/gemtuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Localization of HTLV-I tax proviral DNA in mononuclear cells.
Next Document: Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.